SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IGEN International -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (511)9/21/1999 5:26:00 PM
From: Michael Greene  Read Replies (1) | Respond to of 1025
 
>>He also said that the IGEN-licensed Roche products are growing into most of Roche's 20% market share of a $7 billion market.

This may sound improbable but I also heard Migausky say this at the shareholders meeting. He believes that Roche will be moving most of their diagnostic offerings to the IGEN technology platform over a period of several years. This may or may not happen but jpbrody is quoting him correctly.



To: rkrw who wrote (511)9/21/1999 9:18:00 PM
From: Michael Greene  Respond to of 1025
 
It is worth listening to Migausky's words at the Emerald Research Conference for anyone who hasn't already.

vcall.com
(free registration required)

The following quote occurs about 3/4 through his presentation.
"....Roche has a 20% plus market share in a 7 billion dollar (immunodiagnostics) market and you can do the math, 20% times 7 billion dollars at 9% royalty and it drops straight to our bottom line."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News